Abiopharma

🔍 Mandinach Barry M. (Executive)

Company: VIRTUS INVESTMENT PARTNERS, INC. (VRTS)

Report Date: 2026-03-13

Detailed Transactions and Holdings:

• Sold 741 shares of Common Stock at $126.11 per share (Direct)
  Date: 2026-03-13 | Code: F | equity_swap_involved: 0 | shares_owned_after: 12,722.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 3,093 shares of Common Stock at $126.11 per share (Direct)
  Date: 2026-03-13 | Code: A | equity_swap_involved: 0 | shares_owned_after: 15,815.00 | transaction_form_type: 4 | Footnotes: F2, F3

Footnotes:

• F1: Exempt disposition to the Issuer under Rule 16b-3(e) to satisfy tax withholding obligations arising out of the vesting of restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Company's 2023, 2024 and 2025 Long Term Incentive Plans, previously reported and settled with shares by the Reporting Person.
• F2: These shares comprise an award of RSUs granted to the Reporting Person pursuant to the Company's 2026 Long Term Incentive Plan. Subject to acceleration in certain circumstances, the RSUs are scheduled to vest ratably over the next three years and will be settled for shares of common stock on a one-for-one basis upon vesting.
• F3: This number includes (i) 2,041 RSUs that are scheduled to vest on March 15, 2027, (ii) 1,608 RSUs that are scheduled to vest on March 15, 2028, and (iii) 1,031 RSUs that are scheduled to vest on March 15, 2029.